Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
Key points
- For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge.
- Xalatan eye drops contain the active ingredient latanoprost, which is a type of medicine called a prostaglandin analogue.
- Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck.
- Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869.
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.
"In general, eye drops are an inefficient method of drug delivery that has notoriously poor patient adherence. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications," said Joseph Ciolino, M.D, Mass. Eye and Ear cornea specialist and lead author of the paper.
The contacts were designed with materials that are FDA-approved for use on the eye. The latanoprost-eluting contact lenses were created by encapsulating latanoprost-polymer films in commonly used contact lens hydrogel. Their findings are described online and will be in the January 2014 printed issue of Biomaterials.
"The lens we have developed is capable of delivering large amounts of drug at substantially constant rates over weeks to months," said Professor Daniel Kohane, director of the Laboratory for Biomaterials and Drug Delivery at Boston Children's Hospital.
In vivo, single contact lenses were able to achieve, for one month, latanoprost concentrations in the aqueous humor that were comparable to those achieved with daily topical latanoprost solution, the current first-line treatment for glaucoma.
The lenses appeared safe in cell culture and animal studies. This is the first contact lens that has been shown to release drugs for this long in animal models.
Latanoprost: Prostaglandin Treatment for Glaucoma Age-related health complications often lead to significant deterioration in quality of life when not well managed. Whether you are approaching the latter part of your life, or caring for an aging family member, it is important to know what age-related complications can have long term impact and what costs and benefits are associated with treatment.
In managing an age-related vision complication, such as glaucoma, many senior adults are not only confused about treatment options but also avoid tend to be non-compliant in treatment programs. Glaucoma, as the second leading cause of blindness in adults, is a complication that must be well managed in order to ensure quality of life.
Because conditions such as hypertension, diabetes and even thyroid disorders can create a complication such as glaucoma, regular vision and eye screenings are crucial to the health of the senior adult. In many cases, glaucoma is asymptomatic, meaning the senior adult will not even be aware the complication is of concern.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Eyes, Ears & Teeth →Drug may guard against periodontitis, and related chronic diseases
A drug currently used to treat intestinal worms could protect people from periodontitis, an advanced gum disease, which untreated can erode the structures—including bone—that hold the teeth in the jaw. The research was…
9 November 2013

